You just read:

Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology

News provided by

Eli Lilly and Company

Oct 07, 2019, 06:45 ET